The Food and Drug Administration (FDA) has announced that Avinza (morphine sulfate; Pfizer) extended-release capsules have been discontinued.

Avinza is a CII opioid agonist indicated for the management of severe pain requiring daily, around-the-clock, long-term analgesia and for which alternative opioid therapies are inadequate in adults. Pfizer notified the FDA earlier this year regarding the discontinuation of Avinza. With the availability of Embeda (morphine sulfate and naltrexone HCl) extended-release capsules, the company had decided to remove its non-abuse deterrent morphine formulation from the market.

RELATED: Certain Comorbid Disorders May Lower Opioid Efficacy, Up Abuse Risk

Avinza 30mg, 45mg, 60mg, 75mg, 90mg, and 120mg extended-release capsules have all been discontinued.

For more information call (800) 438-1985 or visit